Drugs /

beta-glucan

Back to Drugs List

Overview

NCI Definition [1]:
A polysaccharide isolated from the cell walls of bacteria, plants, and fungi with immunostimulant and antineoplastic activities. In a solubilized form, beta-glucan binds to a lectin site within complement receptor 3 (CR3) on leukocytes, priming the receptor to trigger cytotoxic degranulation of leukocytes when leukocyte CR3 binds to complement 3 (iC3b)-coated tumors. Thus, the attachment of beta-glucan to CR3 of circulating leukocytes simulates leukocytes to kill iC3b-coated tumor cells in the same way as they kill iC3b-coated yeast. (NCI04)

Clinical Trials

View Clinical Trials for beta-glucan

Beta-glucan has been investigated in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials investigating beta-glucan, 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 2 are no phase specified (2 open).

MYCN Amplification is the most frequent biomarker inclusion criterion for beta-glucan clinical trials.

Neuroblastoma, melanoma, and non-small cell lung carcinoma are the most common diseases being investigated in beta-glucan clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Beta-Glucan
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating beta-glucan and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
immucell wgp, beta glucan, beta glucans, beta-glucans [chemical/ingredient], beta glucan, beta-glucans, b-gluc, beta glucan (substance)
Drug Target(s) [2]:
ITGAM, ITGB2
NCIT ID [1]:
C2678

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.